PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10598117
Filing Date	2006-08-17
First Named Inventor	Harris, Craig Steven
Art Unit	
Examiner Name	
Attorney Docket Number	101401-1P US

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] ¡	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	2000/53185	WO	A1	2000-09-14	Merck & Co. Inc.		☐
	2	2004/017961	WO	A2	2004-03-04	AstraZeneca AB		☐
	3	2004/018479	WO	A1	2004-03-04	AstraZeneca AB		☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.R./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10598117
	Filing Date	2006-08-17
	First Named Inventor	Harris, Craig Steven
	Art Unit	
	Examiner Name	
	Attorney Docket Number	101401-1P US

	4	1998/02430	WO	A1	1998-01-22	Pfizer Pharmaceuticals Inc.		☐
	5	1996/03383	WO	A1	1996-02-08	Eli Lilly and Company		☐
	6	1999/51595	WO	A1	1999-10-14	Merck & Co. Inc		☐
	7	1997/14697	WO	A1	1997-04-24	Takeda Chemical Industries, Inc.		☐
	8	2002/66459	WO	A1	2002-08-29	AstraZeneca AB		☐
	9	2002/92565	WO	A2	2002-11-21	AstraZeneca AB		☐
	10	2004/18480	WO	A1	2004-03-04	AstraZeneca AB		☐
	11	2004/18459	WO	A1	2004-03-04	AstraZeneca AB		☐
	12	2004/18420	WO	A1	2004-03-04	AstraZeneca AB		☐
	13	2005/080402	WO	A1	2005-09-01	AstraZeneca AB		☐
	14	2005/080400	WO	A1	2005-09-01	AstraZeneca AB		☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.R./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10598117
	Filing Date	2006-08-17
	First Named Inventor	Harris, Craig Steven
	Art Unit	
	Examiner Name	
	Attorney Docket Number	101401-1P US

	15	2000/69433	WO	A1	2000-11-23	Merck & Co. Inc		☐
	16	2000/04013	WO	A1	2000-01-27	Merck & Co. Inc		☐
	17	1999/41252	WO	A1	1999-08-19	Merck & Co. Inc		☐
	18	1999/41251	WO	A1	1999-08-19	Merck & Co. Inc		☐
	19	1999/21557	WO	A1	1999-05-06	Merck & Co. Inc		☐
	20	1999/21553	WO	A1	1999-05-06	Merck & Co. Inc		☐
	21	1998/55479	WO	A1	1998-12-10	Merck & Co. Inc		☐
	22	1998/55470	WO	A1	1998-12-10	Merck & Co. Inc		☐
	23	1998/55123	WO	A1	1998-12-10	Merck & Co. Inc		☐
	24	1998/55119	WO	A1	1998-12-10	Merck & Co. Inc		☐
	25	1998/55116	WO	A1	1998-12-10	Merck & Co. Inc		☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.R./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10598117
	Filing Date	2006-08-17
	First Named Inventor	Harris, Craig Steven
	Art Unit	
	Examiner Name	
	Attorney Docket Number	101401-1P US

	26	1997/21707	WO	A1	1997-06-19	Merck & Co. Inc		☐
	27	1997/21704	WO	A1	1997-06-19	Merck & Co. Inc		☐
	28	1997/21703	WO	A1	1997-06-19	Merck & Co. Inc		☐
	29	1997/21435	WO	A1	1997-06-19	Merck & Co. Inc		☐
	30	2000/53602	WO	A1	2000-09-14	Merck & Co. Inc		☐
	31	2002/66477	WO	A2	2002-08-29	AstraZeneca AB		☐
	32	2000/53181	WO	A1	2000-09-14	Merck & Co. Inc		☐
	33	2000/53180	WO	A1	2000-09-14	Merck & Co. Inc		☐
	34	2000/53179	WO	A1	2000-09-14	Merck & Co. Inc		☐
	35	2000/53178	WO	A1	2000-09-14	Merck & Co. Inc		☐
	36	1999/51596	WO	A1	1999-10-14	Merck & Co. Inc		☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.R./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10598117
	Filing Date	2006-08-17
	First Named Inventor	Harris, Craig Steven
	Art Unit	
	Examiner Name	
	Attorney Docket Number	101401-1P US

	37	1999/51234	WO	A1	1999-10-14	Merck & Co. Inc		☐
	38	1999/51233	WO	A1	1999-10-14	Merck & Co. Inc		☐
	39	1999/51232	WO	A1	1999-10-14	Merck & Co. Inc		☐
	40	1999/51231	WO	A1	1999-10-14	Merck & Co. Inc		☐
	41	2002/66478	WO	A1	2002-08-29	AstraZeneca AB		☐
	42	2005/79805	WO	A1	2005-09-01	AstraZeneca AB		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]
	1	ASHTON, W. T. et. al., Substituted Indole-5-carboxamides and –acetamides as Potent Nonpeptide GnRH Receptor Antagonists, Bioorganic & Medicinal Chemistry Letters, 2001, pages 1723-1726, vol. 11.	☐
	2	ASHTON, W. T. et. al., Potent Nonpeptide GnRH Receptor Antagonists Derived from Substituted Indole-5-carboxamides and –acetamides Bearing a Pyridine Side-Chain Terminus, Bioorganic & Medicinal Chemistry Letters, 2001, pages 1727-1731, vol. 11.	☐
	3	ASHTON, W.T. et. al., Orally Bioavailable, Indole-Based Nonpeptide GnRH Receptor Antagonists with High Potency and Functional Activity, Bioorganic and Medicinal Chemistry Letters, 2001, pp. 2597–2602, vol. 11.	☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.R./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10598117
	Filing Date	2006-08-17
	First Named Inventor	Harris, Craig Steven
	Art Unit	
	Examiner Name	
	Attorney Docket Number	101401-1P US

	4	CHU, L. et. al., Initial Structure-Activity Relationship of a Novel Class of Nonpeptidyl GnRH Receptor Antagonists: 2-Arylindoles, Bioorganic and Medicinal Chemistry Letters, 2001, pages 509–513, vol. 11.	☐
	5	CHU, L. et. al., SAR Studies of Novel 5-Substituted 2-Arylindoles as Nonpeptidyl GnRH Receptor Antagonists, Bioorganic and Medicinal Chemistry Letters, 2001, pages 515–517, vol. 11.	☐
	6	FREIDINGER, R. M., Nonpeptidic ligands for peptide and protein receptors, Current Opinion in Chemical Biology, 1999, pages 395–406, vol. 3.	☐
	7	GOULET, M, T., Gonadotropin Releasing Hormone Antagonists, Annual Reports in Medicinal Chemistry,1995, pages 169 – 178, vol. 30.	☐
	8	LIN, P. et. al., 2-(3,5-Dimethylphenyl)tryptamine Derivatives That Bind to the GnRH Receptor, Bioorganic & Medicinal Chemistry Letters, 2001, pp. 1073 – 1076, vol. 11.	☐
	9	LIN, P. et. al., Heterocyclic Derivatives of 2-(3,5-Dimethylphenyl)tryptamine as GnRH Receptor Antagonists, Bioorganic & Medicinal Chemistry Letters, 2001, pages 1077 – 1080, vol. 11.	☐
	10	SIMOENE, J. P. et. al., Synthesis of chiral β-methyl tryptamine-derived GnRH antagonists, 2001, Tetrahedron Letters, pages 6459 – 6461, vol. 42.	☐
	11	WALSH, T. F., et. al., A convergent synthesis of (S)-β-methyl-2-aryltryptamine based gonadotropin releasing hormone antagonists, 2001, Tetrahedon, pages 5233 – 5241, vol. 57.	☐
	12	YOUNG, J. R. et. al., 2-Arylindoles as Gonadotropin Releasing Hormone (GnRH) Antagonists: Optimization of the Tryptamine Side Chain, Bioorganic & Medicinal Chemistry Letters, 2002, pages 827–832, vol. 12.	☐
	13	UJJAINWALLA, F. & WALSH, T. F., Total synthesis of 6- and 7-azaindole derived GnRH antagonists, Tetrahedron Letters, 2001, pages 6441 – 6445, vol. 42.	☐
	14	SIMEONE, J. P., et. al., Modification of the Pyridine Moiety of Non-peptidyl Indole GnRH Receptor Antagonists, Bioorganic & Medicinal Chemistry Letters, 2002, pages 3329 – 3332, vol. 12.	☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.R./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10598117
	Filing Date	2006-08-17
	First Named Inventor	Harris, Craig Steven
	Art Unit	
	Examiner Name	
	Attorney Docket Number	101401-1P US

	15	GIBBS, J. B. & OLIFF, A., Pharmaceutical Research in Molecular Oncology, Cell, 1994, pages 193 – 198, vol. 79.	☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Craig Ricci/	Date Considered	10/06/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.R./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10598117
Filing Date	2006-08-17
First Named Inventor	Harris, Craig Steven
Art Unit	
Examiner Name	
Attorney Docket Number	101401-1P US

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☑ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Lucy Padget/	Date (YYYY-MM-DD)	2007-03-15
Name/Print	Lucy Padget	Registration Number	L0074

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.R./

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.R./